Amgen Inc. Q3 2024 Results Filed
Ticker: AMGN · Form: 10-Q · Filed: 2024-10-31T00:00:00.000Z
Sentiment: neutral
Topics: earnings, financials, biotech
Related Tickers: AMGN
TL;DR
**AMGN Q3 2024 RESULTS ARE IN - CHECK THE NUMBERS**
AI Summary
Amgen Inc. reported its third-quarter results for the period ending September 30, 2024. The company's filing indicates financial activities and product sales for the third quarter of 2024 and year-to-date, comparing them to the same periods in 2023. Specific financial figures and product segment details are provided within the report.
Why It Matters
This filing provides investors with the latest financial performance data for Amgen, a major biotechnology company, allowing them to assess its current health and future prospects.
Risk Assessment
Risk Level: low — This is a routine quarterly financial filing with no immediate red flags.
Key Numbers
- 2024-09-30 — Reporting Period End Date (Indicates the end of the fiscal quarter for which results are reported.)
- 2024-10-31 — Filing Date (The date Amgen officially submitted this 10-Q to the SEC.)
- 2024-01-01 to 2024-09-30 — Year-to-Date Period (Covers the first nine months of the fiscal year 2024 for financial comparison.)
- 2023-01-01 to 2023-09-30 — Prior Year-to-Date Period (Provides a basis for year-over-year performance comparison.)
- 2024-07-01 to 2024-09-30 — Q3 2024 Period (Specific financial data for the third quarter of 2024.)
Key Players & Entities
- AMGEN INC (company) — Filer of the 10-Q report
- 20240930 (date) — End of the reporting period
- 20241031 (date) — Date the filing was made
- 2024 Q3 (period) — Quarter being reported
FAQ
What were Amgen's total revenues for the third quarter of 2024?
The filing indicates the period from 2024-07-01 to 2024-09-30 for Q3 2024 product and service other revenue, but specific total revenue figures are not detailed in this header information.
How do the year-to-date revenues for 2024 compare to 2023?
The filing provides the date ranges for year-to-date periods (2024-01-01 to 2024-09-30 and 2023-01-01 to 2023-09-30) for product and service other revenue, allowing for comparison, but specific figures are not in this section.
What is the fiscal year end for Amgen?
Amgen's fiscal year ends on December 31 (1231).
When was this 10-Q filing submitted to the SEC?
This 10-Q filing was submitted on October 31, 2024 (20241031).
What is the primary business of Amgen Inc. according to the filing?
Amgen Inc. is primarily involved in Biological Products (No Diagnostic Substances), classified under SIC code 2836.
From the Filing
0000318154-24-000044.txt : 20241031 0000318154-24-000044.hdr.sgml : 20241031 20241030184320 ACCESSION NUMBER: 0000318154-24-000044 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 83 CONFORMED PERIOD OF REPORT: 20240930 FILED AS OF DATE: 20241031 DATE AS OF CHANGE: 20241030 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMGEN INC CENTRAL INDEX KEY: 0000318154 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 953540776 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37702 FILM NUMBER: 241411854 BUSINESS ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 BUSINESS PHONE: (805)447-1000 MAIL ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 FORMER COMPANY: FORMER CONFORMED NAME: AMGEN DATE OF NAME CHANGE: 19870305 10-Q 1 amgn-20240930.htm 10-Q amgn-20240930 0000318154 false 2024 Q3 12/31 http://fasb.org/srt/2024#PartnershipInterestMember http://fasb.org/srt/2024#PartnershipInterestMember xbrli:shares iso4217:USD iso4217:USD xbrli:shares amgn:segment amgn:Segment xbrli:pure amgn:notice amgn:case iso4217:EUR iso4217:GBP 0000318154 2024-01-01 2024-09-30 0000318154 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0000318154 amgn:A2.00SeniorNotesDue2026Member 2024-01-01 2024-09-30 0000318154 2024-10-25 0000318154 us-gaap:ProductMember 2024-07-01 2024-09-30 0000318154 us-gaap:ProductMember 2023-07-01 2023-09-30 0000318154 us-gaap:ProductMember 2024-01-01 2024-09-30 0000318154 us-gaap:ProductMember 2023-01-01 2023-09-30 0000318154 us-gaap:ProductAndServiceOtherMember 2024-07-01 2024-09-30 0000318154 us-gaap:ProductAndServiceOtherMember 2023-07-01 2023-09-30 0000318154 us-gaap:ProductAndServiceOtherMember 2024-01-01 2024-09-30 0000318154 us-gaap:ProductAndServiceOtherMember 2023-01-01 2023-09-30 0000318154 2024-07-01 2024-09-30 0000318154 2023-07-01 2023-09-30 0000318154 2023-01-01 2023-09-30 0000318154 2024-09-30 0000318154 2023-12-31 0000318154 us-gaap:CommonStockMember 2023-12-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2023-12-31 0000318154 us-gaap:RetainedEarningsMember 2023-12-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000318154 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000318154 2024-01-01 2024-03-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0000318154 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000318154 us-gaap:CommonStockMember 2024-03-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2024-03-31 0000318154 us-gaap:RetainedEarningsMember 2024-03-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000318154 2024-03-31 0000318154 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0000318154 2024-04-01 2024-06-30 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0000318154 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0000318154 us-gaap:CommonStockMember 2024-06-30 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2024-06-30 0000318154 us-gaap:RetainedEarningsMember 2024-06-30 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0000318154 2024-06-30 0000318154 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0000318154 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0000318154 us-gaap:CommonStockMember 2024-09-30 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2024-09-30 0000318154 us-gaap:RetainedEar